Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3923 Target Snapshot

Nischarin · SINGLE PROTEIN · Homo sapiens

202Compounds
38Assays
10Approved Drugs
296.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Nischarin shows approved-linked disease relevance led by hypertension. 2 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q9Y2I1. Start with hypertension, then reuse UniProt Q9Y2I1 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with hypertension, then reuse UniProt Q9Y2I1 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 2 linked drugs
Open source guide
Disease program
hypertension

Nischarin shows approved-linked disease relevance led by hypertension. 2 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with hypertension because it currently carries approved-linked support. Linked drugs include MOXONIDINE, RILMENIDINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Nischarin as ChEMBL target CHEMBL3923, mapped to UniProt Q9Y2I1. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Nischarin
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3923
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9Y2I1
Nischarin
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Nischarin is the right protein anchor across sources, using UniProt Q9Y2I1 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why hypertension is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelNischarin
UniProt AccessionQ9Y2I1
Component TypeProtein
Sequence Length1504 aa

Nischarin

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Nischarin, mapped to UniProt Q9Y2I1. Sequence length is 1504 aa.

Mapped IDQ9Y2I1
Review nameNischarin
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Nischarin shows approved-linked disease relevance led by hypertension. 2 more disease programs remain visible in the same review block.

Approved-linked Approved
hypertension
2 linked drugs · 2 direct · 2 efficacy
Linked drugMOXONIDINE
Linked drugRILMENIDINE
Late clinical Phase III
heart disease
1 linked drug · 1 direct · 1 efficacy
Linked drugMOXONIDINE
Mechanism-linked
orthostatic hypotension
1 linked drug · 1 direct · 1 efficacy
Linked drugMOXONIDINE
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with hypertension because it currently carries approved-linked support. Linked drugs include MOXONIDINE, RILMENIDINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasehypertension
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

10
Approved
1
Phase III
4
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC5019.0
KI277.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3546401 9.66 Ki 0.22 Preclinical
CHEMBL266155 9.2 Ki 0.631 Preclinical
CHEMBL14097 9.1 Ki 0.7943 Preclinical
CHEMBL14640 9.0 Ki 1.0 Preclinical
CHEMBL2092861 8.97 Ki 1.072 Preclinical
CHEMBL14107 8.9 Ki 1.259 Preclinical
CHEMBL13698 8.8 Ki 1.585 Preclinical
CHEMBL418536 8.8 Ki 1.585 Preclinical
CHEMBL404505 8.8 Ki 1.585 Preclinical
CHEMBL14012 8.7 Ki 1.995 Clinical
Distribution

pChEMBL Value Distribution

35
5.0
19
5.5
33
6.0
32
6.5
57
7.0
30
7.5
37
8.0
18
8.5
3
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

TIZANIDINE
CHEMBL1079
Approved 1996
MOXONIDINE
CHEMBL19236
Approved 1991
RILMENIDINE
CHEMBL289480
Approved 1987
OXYMETAZOLINE
CHEMBL762
Approved 1986
GUANFACINE
CHEMBL862
Approved 1986
GUANABENZ
CHEMBL420
Approved 1982
CLONIDINE
CHEMBL134
Approved 1974
NAPHAZOLINE
CHEMBL761
Approved 1971
PHENTOLAMINE
CHEMBL597
Approved 1952
Assay Landscape

Assay Landscape

38
Total Assays
216
Tested Compounds
1
Assay Types
Binding — 38 assays, 216 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 27 42 6.8
assay format 6 144 7.1
cell-based format 4 15 6.6
tissue-based format 1 15 6.5

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine